Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose
Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose
复制标题
DOI:
10.1148/radiology.199.3.8638000
复制
发表时间:
1996-06-01
期刊:
影响因子:
19.7
通讯作者:
Wahl, RL
中科院分区:
文献类型:
--
作者:
Shreve, PD;Grossman, HB;Wahl, RL
PURPOSE: To evaluate the accuracy of positron emission tomography (PET) with 2-deoxy-2[fluorine-18]fluoro-D-glucose (FDG) in the detection of osseous and soft-tissue metastases of prostate cancer.MATERIALS AND METHODS: Thirty-four patients (mean age, 71 years) with biopsy-proved prostate cancer and known or suspected metastatic disease were examined. Blinded interpretation of the PET images was compared with bone scan, CT, and clinical follow-up findings.RESULTS: In 202 untreated osseous metastases in 22 patients, the sensitivity of FDG PET was 65% (131 of 202 metastases), with a positive predictive value of 98% (131 of 133 positive findings). The estimated standardized uptake value in metastases was 2.1-5.7. Soft-tissue metastases to the lymph nodes or liver were identified, but evaluation of pelvic lymph node metastases was severely limited because of bladder tracer activity.CONCLUSION: FDG PET can help identify osseous and soft-tissue metastases of prostate cancer with a high positive predictive value but is less sensitive than bone scintigraphy in the identification of osseous metastases.